Summary of Amgen Conference Call Company Overview - **Company**: Amgen - **Key Participants**: Peter Griffith (CFO), Jasper van Grunsven (SVP of Rare Disease), Casey Capparelli (VP of Investor Relations) [8][1] Core Industry Insights - **Strong Portfolio Performance**: In 2025, Amgen reported strong momentum with 13 products delivering double-digit growth, 14 products exceeding $1 billion in annual sales, and 18 products achieving record performance [8][9] - **Key Growth Drivers**: The growth is supported by six key drivers: Repatha, Evenity, Tezspire, rare disease portfolio, innovative oncology, and biosimilars [8][9] - **Rare Disease Portfolio**: Generated $5 billion in sales in 2025, up 14% year-over-year, with significant contributions from UPLIZNA, which grew 73% due to new indications and geographic expansion [9][31] Financial Highlights - **Revenue and Earnings Growth**: Amgen experienced double-digit growth in both revenue and earnings per share in 2025 [8][9] - **Biosimilars Performance**: The biosimilars portfolio generated $3 billion in sales in 2025, growing 37% year-over-year, driven by strong uptake of Pavblu [11][20] - **Quarterly Expectations**: Anticipated seasonal headwinds in Q1 due to insurance cycles and historical sales patterns, particularly for Otezla and IMRALDI [14][15] Product-Specific Insights - **UPLIZNA**: Expected to continue strong growth with a focus on new indications and a competitive profile in the market [31][36] - **MariTide**: Positioned as a differentiated treatment for obesity and related conditions, with six global Phase III studies underway. Monthly dosing is expected to improve patient adherence [12][25][62] - **IMDELLTRA**: A bispecific T-cell engager for small cell lung cancer, rapidly becoming the standard of care with ongoing Phase III studies [10][19] Pipeline and Future Growth - **Pipeline Development**: 2026 is set to be a year of disciplined data generation across multiple Phase II and III programs, with a focus on long-term growth [12][20] - **Dazodalibep (DAS)**: Targeting Sjögren's disease, with a significant unmet need and promising Phase II data [50][51] Competitive Landscape - **Market Positioning**: Amgen is aware of competitive pressures, particularly in the obesity market from companies like Lilly and Novo, but believes its established commercial capabilities will provide a competitive edge [68][69] - **M&A Environment**: Amgen maintains a strong balance sheet and is open to M&A opportunities, focusing on innovation and integration capabilities [70][72] Additional Considerations - **Adherence and Patient Experience**: Emphasis on improving patient adherence through less frequent dosing regimens, which is crucial for chronic conditions [62][63] - **Commercial Strategy**: Amgen is strategizing on how to effectively position MariTide in a rapidly evolving market, considering both commercial and consumer segments [58][59]

Summary of Amgen Conference Call Company Overview - **Company**: Amgen - **Key Personnel**: Peter Griffith (CFO), Casey (IR), Jasper van Grunsven (Rare Disease) Core Industry Insights - **Strong Portfolio Performance**: In 2025, Amgen reported strong momentum with 13 products delivering double-digit growth, 14 products exceeding $1 billion in annual sales, and 18 products achieving record performance [7][8][21] - **Key Growth Drivers**: The growth is supported by six key drivers: Repatha, Evenity, Tezspire, rare disease portfolio, innovative oncology, and biosimilars [7][8][14] - **Rare Disease Portfolio**: Generated $5 billion in sales in 2025, up 14% year-over-year, with significant contributions from UPLIZNA, which grew 73% [8][35] Financial Highlights - **Revenue and Earnings Growth**: Double-digit growth in both revenue and earnings per share in 2025 [7] - **Biosimilars Performance**: The biosimilars portfolio generated $3 billion in product sales in 2025, growing 37% year-over-year, with strong uptake of Pavblu [9][18] - **Quarterly Expectations**: Anticipated seasonal Q1 headwinds due to insurance cycles and historical sales patterns for certain products [12][13] Product-Specific Insights - **UPLIZNA**: - Significant growth driven by new patient acquisition and geographic expansion [8][35] - Expected continued growth with new indications and ongoing studies in autoimmune diseases [8][38] - **Innovative Oncology**: - IMDELLTRA has become a standard of care in small cell lung cancer, with ongoing Phase 3 studies [9][17] - Xaluritamig is being evaluated for metastatic castrate-resistant prostate cancer [9] - **MariTide**: - Positioned as a differentiated treatment for obesity and related conditions, with six global Phase 3 studies underway [10][28] - Monthly dosing is expected to improve patient adherence and long-term outcomes [76][78] Competitive Landscape - **Market Positioning**: Amgen is focused on maintaining a competitive edge in the obesity market against formidable competitors like Lilly and Novo [80] - **M&A Strategy**: Amgen is open to mergers and acquisitions, focusing on innovation and effective integration to enhance shareholder value [85][86] Future Outlook - **Pipeline Development**: 2026 is expected to be a year of disciplined data generation across multiple Phase 2 and Phase 3 programs [10][11] - **Long-Term Growth**: Amgen is well-positioned for sustained long-term growth with a diversified portfolio and a strong pipeline [13][22] Additional Considerations - **Adherence Challenges**: Current treatment burdens and dosing frequencies are barriers to long-term persistence on therapy, which MariTide aims to address [76][78] - **Safety Profile of DAS**: Dazodalibep is engineered to avoid adverse events seen in previous therapies targeting the same pathway, with a favorable safety profile observed in Phase 2 studies [64][66] This summary encapsulates the key points discussed during the Amgen conference call, highlighting the company's performance, product insights, financial outlook, and strategic positioning within the industry.

Q4 '25 Earnings Call February 3, 2026 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance o ...